Loading clinical trials...
Loading clinical trials...
Investigation on Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
Conditions
Interventions
NNC9204-1706 A
Placebo
Locations
1
United States
Novo Nordisk Investigational Site
Baltimore, Maryland, United States
Start Date
March 20, 2017
Primary Completion Date
August 31, 2017
Completion Date
August 31, 2017
Last Updated
October 5, 2018
NCT01143454
NCT07472881
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions